Axitinib multi target TKI

AG-013736 - AG013736 - AG 013736 - Inlyta

Renal-cell carcinoma (advanced)

All type of patients:  2 trials  - AXIS (Rini) - Qin

axitinib vs sorafenib

No demonstrated result

suggested progression or death (progression free survival PFS) by 34% (not demonstrated)




- About - Browse pathology | treatment - Site map - Credits Made with in Lyon - Contact us - Privacy policy - Licence Creative Commons